{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:56:57Z","timestamp":1790265417423,"version":"4.1.0"},"reference-count":45,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2014,7,10]],"date-time":"2014-07-10T00:00:00Z","timestamp":1404950400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0102436","type":"journal-article","created":{"date-parts":[[2014,7,10]],"date-time":"2014-07-10T18:05:13Z","timestamp":1405015513000},"page":"e102436","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":116,"title":["Tocilizumab, a Proposed Therapy for the Cachexia of Interleukin6-Expressing Lung Cancer"],"prefix":"10.1371","volume":"9","author":[{"given":"Katsutoshi","family":"Ando","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiyuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoyasu","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiro","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tokuhide","family":"Doi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Ohe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiaki","family":"Koizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuto","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhisa","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,7,10]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"K Fearon","year":"2011","journal-title":"Lancet Oncol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0149-2918(05)80001-3","article-title":"Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern cooperative oncology group","volume":"69","author":"WD Dewys","year":"1980","journal-title":"Am J Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/nrc927","article-title":"Cachexia in cancer patients","volume":"2","author":"MJ Tisdale","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/ajcn\/83.6.1345","article-title":"Definition of cancer cachexia: effect of weight loss, reduced food intake and systemic inflammation on functional status and prognosis","volume":"83","author":"KCH Fearon","year":"2006","journal-title":"Am J Clin Nutr"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/qjmed\/hci127","article-title":"Cancer cachexia","volume":"98","author":"JN Gordon","year":"2005","journal-title":"QJM"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1152\/physrev.00016.2008","article-title":"Mechanisms of cancer cachexia","volume":"89","author":"MJ Tisdale","year":"2009","journal-title":"Physiol Rev"},{"key":"ref7","first-page":"159","article-title":"Pathogenesis of cancer cachexia","volume":"1","author":"MJ Tisdale","year":"2003","journal-title":"J Support Oncol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1093\/jnci\/89.23.1763","article-title":"Biology of cachexia","volume":"89","author":"MJ Tisdale","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1200\/JCO.1995.13.10.2600","article-title":"Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients","volume":"13","author":"AJ Staal-van den Brekel","year":"1995","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.immunol.23.021704.115806","article-title":"Interleukin-6: From basic science to medicine\u201340 years in immunology","volume":"23","author":"T Kishimoto","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1002\/cncr.22999","article-title":"Interleukin-6 and its receptor in cancer: implications for translational therapeutics","volume":"110","author":"DS Hong","year":"2007","journal-title":"Cancer"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/bjc.1993.174","article-title":"Interleukin-6 cDNA transfected Lewis lung carcinoma cells show unaltered net tumour growth rate but cause weight loss and shrten survival in syngenic mice","volume":"67","author":"Y Ohe","year":"1993","journal-title":"Br J Cancer"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1200\/JCO.2012.44.2020","article-title":"Possible role for tocilizumab, an anti-interleukin-6 receptor antibody, in treating cancer cachexia","volume":"31","author":"K Ando","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0165-2478(02)00202-X","article-title":"Characterization of anti-mouse interleukin-6 receptor antibody","volume":"84","author":"M Okazaki","year":"2002","journal-title":"Immunol Lett"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/eji.1830180817","article-title":"Interleukin 6, the third mediator of acute-phase reaction, modulates hepatic protein synthesis in human and mouse. Comparison with interleukin 1 beta and tumor necrosis factor-alpha","volume":"18","author":"G Ramadori","year":"1988","journal-title":"Eur J Immunol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2220\/biomedres.30.47","article-title":"Novel models of cancer-related anemia in mice inoculated with IL-6-producing tumor cells","volume":"30","author":"K Mori","year":"2009","journal-title":"Biomed Res"},{"key":"ref17","first-page":"38","article-title":"Studies in a tumor spectrum. III. The effect of phosphoramides on the growth of a variety of mouse and rat tumors","volume":"15","author":"K Sugiura","year":"1955","journal-title":"Cancer Res"},{"key":"ref18","first-page":"4509","article-title":"Drug treatments for metastasis of the Lewis lung carcinoma: lack of correlation between inhibition of lung metastasis and survival","volume":"49","author":"RL Merriman","year":"1989","journal-title":"Cancer Res"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/ijc.10261","article-title":"Osteopontin induces angiogenesis of murine neuroblastoma cells in mice","volume":"98","author":"F Takahashi","year":"2002","journal-title":"Int J Cancer"},{"key":"ref20","first-page":"976926","article-title":"Hochuekkito (TJ-41), a Kampo Formula, Ameliorates Cachexia Induced by Colon 26 Adenocarcinoma in Mice","volume":"2012","author":"S Yae","year":"2012","journal-title":"Evid Based Complement Alternat Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1158\/1078-0432.CCR-09-0287","article-title":"Humanized Anti-Interleukin-6 Receptor Antibody Suppresses Tumor Angiogenesis and In vivo Growth of Human Oral Squamous Cell Carcinoma","volume":"15","author":"S Shinriki","year":"2009","journal-title":"Clin Cancer Res"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4137\/CMAMD.S7371","article-title":"Safety and Efficacy of Tocilizumab for the Treatment of Rheumatoid Arthritis","volume":"5","author":"A Ogata","year":"2012","journal-title":"Clin Med Insights Arthritis Musculoskelet Disord"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1182\/blood-2004-12-4602","article-title":"Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease","volume":"106","author":"N Nishimoto","year":"2005","journal-title":"Blood"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0304-3835(03)00286-6","article-title":"Osteopontin overproduced by tumor cells acts as a potent angiogenic factor contributing to tumor growth","volume":"198","author":"M Hirama","year":"2003","journal-title":"Cancer Lett"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/j.intimp.2008.08.008","article-title":"Soph-ocarpine and matrine inhibit the production of TNF- \u03b1 and IL-6 in murine macrophages and prevent cachexia-related symptoms induced by colon26 adenocarcinoma in mice","volume":"8","author":"Y Zhang","year":"2008","journal-title":"Int Immunopharmacol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/(SICI)1097-0215(19961127)68:5<637::AID-IJC14>3.0.CO;2-Z","article-title":"Anti-interleukin-6 receptor antibody prevents muscle atrophy in colon-26 adeno-carcinoma-bearing mice with modulation of lysosomal and ATP-ubiquitin-dependent proteolytic pathways","volume":"68","author":"J Fujita","year":"1996","journal-title":"Int J Cancer"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1109\/TAC.1974.1100705","article-title":"A new look at statistical model identification","volume":"19","author":"H Akaike","year":"1974","journal-title":"IEEE Transactions on Automatic Control"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3758\/BF03206482","article-title":"AIC model selection using Akaike weights","volume":"11","author":"EJ Wagenmakers","year":"2004","journal-title":"Psychon Bull Rev"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s11605-008-0505-z","article-title":"Cachexia worsens prognosis in patients with resectable pancreatic cancer","volume":"12","author":"J Bachmann","year":"2008","journal-title":"J Gastrointest Surg"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"e41883","DOI":"10.1371\/journal.pone.0041883","article-title":"The relationships between body composition and the systemic inflammatory response in patients with primary operable colorectal cancer","volume":"7","author":"CH Richards","year":"2012","journal-title":"PLoS One"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.lungcan.2011.05.009","article-title":"Mini Nutritional Assessment (MNA) and biochemical markers of cachexia in metastatic lung cancer patients: interrelations and associations with prognosis","volume":"74","author":"I Gioulbasanis","year":"2011","journal-title":"Lung Cancer"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1172\/JCI113000","article-title":"Study of the molecular mechanism of decreased liver synthesis of albumin in inflammation","volume":"79","author":"HJ Moshage","year":"1987","journal-title":"J Clin Invest"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1002\/1097-0142(19950415)75:8<2077::AID-CNCR2820750808>3.0.CO;2-9","article-title":"Acute-phase protein response and survival duration of patients with pancreatic cancer","volume":"75","author":"JS Falconer","year":"1995","journal-title":"Cancer"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.urology.2012.10.055","article-title":"Using preoperative albumin levels as a surrogate marker for outcomes after radical cystectomy for bladder cancer","volume":"81","author":"JW Lambert","year":"2013","journal-title":"Urology"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/jjco\/hyt043","article-title":"Serum Albumin is an Important Prognostic Factor for Carotid Blowout Syndrome","volume":"43","author":"HJ Lu","year":"2013","journal-title":"Jpn J Clin Oncol"},{"key":"ref36","first-page":"751","article-title":"Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study","volume":"69","author":"E Bruera","year":"1985","journal-title":"Cancer Treat Rep"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/0277-5379(89)90354-4","article-title":"Methylprednisolone as palliative therapy for female terminal cancer patients. The methylprednisolone female preterminal cancer study group","volume":"25","author":"T Popiela","year":"1989","journal-title":"Eur J Cancer Clin Oncol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1200\/JCO.2004.03.103","article-title":"Appetite and cancer-associated anorexia: A review","volume":"22","author":"MP Davis","year":"2004","journal-title":"J Clin Oncol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","article-title":"Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti\u2013IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease","volume":"112","author":"N Nishimoto","year":"2008","journal-title":"Blood"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"896","DOI":"10.4049\/jimmunol.177.2.896","article-title":"Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells","volume":"177","author":"AG Jarnicki","year":"2006","journal-title":"J. Immunol"},{"key":"ref41","first-page":"338","article-title":"Mechanisms of suppression by suppressor T cells. Nat","volume":"6","author":"H von Boehmer","year":"2005","journal-title":"Immunol"},{"key":"ref42","first-page":"828","article-title":"Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat","volume":"13","author":"S Nagaraj","year":"2007","journal-title":"Med"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"812","DOI":"10.4049\/jimmunol.1103797","article-title":"The key role of IL-6-arginase cascade for inducing dendritic cell-dependent CD4(+) T cell dysfunction in tumor-bearing mice","volume":"190","author":"Y Narita","year":"2013","journal-title":"J Immunol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4137\/CMAMD.S7371","article-title":"Safety and efficacy of tocilizumab for the treatment of rheumatoid arthritis","volume":"5","author":"A Ogata","year":"2012","journal-title":"Clin Med insights Arthritis Musculoskelet Disord"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1200\/JCO.2013.50.4324","article-title":"Reply to Berti, et al","volume":"31","author":"K Ando","year":"2013","journal-title":"J Clin Oncol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0102436","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T17:45:47Z","timestamp":1565631947000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0102436"}},"subtitle":[],"editor":[{"given":"Rossella","family":"Rota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,7,10]]},"references-count":45,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2014,7,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0102436","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,10]]}}}